About Us

Management Team

Alexandros Chatgilialoglu, PhD, MBA

Co-Founder, CEO

Enrico Menzolini

President, CFO, Investor

Paola Poggi, PhD

Co-Founder, CTO, Responsible for QMS compliance

Alessandro Curti



Remembrane leads the cell culture technology a step forward, by envisaging the cell membrane network as a fundamental and indispensable actor of most cellular processes.

Our Science

Restoring In Vivo-Like Membrane Lipidomics Promotes Exosome Trophic Behavior from Human Placental Mesenchymal Stromal/Stem Cells

Cavallini C, Zannini C, Olivi E, Tassinari R, Taglioli V, Rossi M, Poggi P, Chatgilialoglu A, Simonazzi G, Alviano F, Bonsi L, Ventura C. - Cell Transplant. 2018 Jan;27(1):55-69.

Restored in vivo-like membrane lipidomics positively influence in vitro features of mesenchymal stem cells derived from human placenta

Chatgilialoglu A, Rossi M, Alviano F, Poggi P, Zannini C, Marchionni C, Ricci F, Tazzari PL, Taglioli V, Calder PC, Bonsi L. - Stem Cell Res Ther. 2017 Feb 7;8(1):31.

Membrane fatty acid heterogeneity of leukocyte classes is altered during in vitro cultivation but can be restored with ad-hoc lipid supplementation

Poggi P., Mirabella R., Neri S., Assirelli E., Dolzani P., Mariani E., Calder P.C., Chatgilialoglu A. - Lipids Health Dis. 2015 Dec 24;14(1):165.

Membrane lipidome reorganization correlates with the fate of neuroblastoma cells supplemented with fatty acids

Bolognesi A, Chatgilialoglu A, Polito L, Ferreri C.
PLoS One. 2013;8(2):e55537. doi: 10.1371/journal.pone.0055537. Epub 2013 Feb 6


Cell Culturing is a widespread technology growing at an annual CAGR of 10.7%, with an expected worldwide market of 37 B USD by 2022 (Cit. from Grand View Research, 2016). Main trends pushing the sector are the biomanufacturing of biosimilars and vaccines, the boom of stem cells and regenerative medicine approaches, the impressive results of the new CAR-T immunotherapies, the potentiality of gene and cell therapy, etc.

Our Refeed technology can be applied to any of the above-mentioned cell culture applications, even to new revolutionary approaches such as the development of laboratory meat or the production of bioplastics and bioethanol.

The world is already requiring more efficient cell culturing solutions to meet current research and production challenges. We keep getting a wide variety of requests from potential customers and most of the time we can not provide them a matching Proof-Of-Concept which would convince them to trust and try our technology for their application.

This is the reason why we look for further investors that can guarantee us the necessary economic resources for the creation of powerful Proof-Of-Concepts in new cell culture applications and increase our portfolio with new revolutionary Refeed products. Contact us at [email protected] and we will be glad to share our up-to-date Investor Pitch with you.

  • 2010Company Foundation

  • 2012Seed Investment

  • Laboratory set up

  • 20141° customer

  • 2015ISO9001 certification

  • 1° publication

  • 20161° POC in Biomanufacturing

  • Beginning of road to GMP

  • 2° publication

  • H2020 SME instrument Ph1

  • 20171° POC in Cell Therapy

  • H2020 SME instrument Ph2 “Seal of Excellence”

  • H2020 ERA CoBioTech grant

  • 20183° publication

  • H2020 Permides grant

  • COST grant